CRISPR-Cas3 and type I restriction-modification team up against blaKPC-IncF plasmid transfer in Klebsiella pneumoniae
BMC Microbiology · 03.07.2024 · 24 (1)
DOI: 10.1186/s12866-024-03381-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMC Microbiology, online erschienen am 03.07.2024. Verfasst von Yang Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Plasmids, CRISPR-Cas Systems, Conjugation, Genetic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Sailing Program.
Abstract (Originalsprache)
Objective
We explored whether the Clustered regularly interspaced short palindromic repeat (CRISPR)-Cas and restriction-modification (R-M) systems are compatible and act together to resist plasmid attacks.
Methods
932 global whole-genome sequences from GenBank, and 459 K. pneumoniae isolates from six provinces of China, were collected to investigate the co-distribution of CRISPR-Cas, R-M systems, and bla KPC plasmid. Conjugation and transformation assays were applied to explore the anti-plasmid function of CRISPR and R-M systems.
Results
We found a significant inverse correlation between the presence of CRISPR and R-M systems and bla KPC plasmids in K. pneumoniae , especially when both systems cohabited in one host. The multiple matched recognition sequences of both systems in bla KPC -IncF plasmids (97%) revealed that they were good targets for both systems. Furthermore, the results of conjugation assay demonstrated that CRISPR-Cas and R-M systems in K. pneumoniae could effectively hinder bla KPC plasmid invasion. Notably, CRISPR-Cas and R-M worked together to confer a 4-log reduction in the acquisition of bla KPC plasmid in conjugative events, exhibiting robust synergistic anti-plasmid immunity.
Conclusions
Our results indicate the synergistic role of CRISPR and R-M in regulating horizontal gene transfer in K. pneumoniae and rationalize the development of antimicrobial strategies that capitalize on the immunocompromised status of KPC-KP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
- Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Department of Laboratory Medicine, Shanghai Medical College, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Clinical Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China. 18702195157@163.com.
- Department of Laboratory Medicine, Shanghai Medical College, Huashan Hospital, Fudan University, Shanghai, China. jiangxi2154@sina.com.
Förderung
- National Natural Science Foundation of China
- Shanghai Sailing Program
Zitieren
APA
Yang, Y., Zhou, P., Tian, D., Wang, W., Zhou, Y., & Jiang, X. (2024). CRISPR-Cas3 and type I restriction-modification team up against blaKPC-IncF plasmid transfer in Klebsiella pneumoniae. BMC Microbiology, 24(1). https://doi.org/10.1186/s12866-024-03381-7
Vancouver
Yang Y, Zhou P, Tian D, Wang W, Zhou Y, Jiang X. CRISPR-Cas3 and type I restriction-modification team up against blaKPC-IncF plasmid transfer in Klebsiella pneumoniae. BMC Microbiology. 2024;24(1). doi:10.1186/s12866-024-03381-7
BibTeX
@article{Yang2024,
author = {Yang, Yang and Zhou, Peiyao and Tian, Dongxing and Wang, Weiwen and Zhou, Ying and Jiang, Xiaofei},
title = {CRISPR-Cas3 and type I restriction-modification team up against blaKPC-IncF plasmid transfer in Klebsiella pneumoniae},
journal = {BMC Microbiology},
year = {2024},
volume = {24},
number = {1},
doi = {10.1186/s12866-024-03381-7}
}
EUVIMED